[go: up one dir, main page]

MX2021013602A - Inhibidores de jak. - Google Patents

Inhibidores de jak.

Info

Publication number
MX2021013602A
MX2021013602A MX2021013602A MX2021013602A MX2021013602A MX 2021013602 A MX2021013602 A MX 2021013602A MX 2021013602 A MX2021013602 A MX 2021013602A MX 2021013602 A MX2021013602 A MX 2021013602A MX 2021013602 A MX2021013602 A MX 2021013602A
Authority
MX
Mexico
Prior art keywords
jak inhibitors
jak
inhibitors
disorders
diseases
Prior art date
Application number
MX2021013602A
Other languages
English (en)
Inventor
Jason Harris
Raju Mohan
John Nuss
Shendong Yuan
Original Assignee
Vimalan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vimalan Biosciences Inc filed Critical Vimalan Biosciences Inc
Publication of MX2021013602A publication Critical patent/MX2021013602A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

En el presente documento se describen los inhibidores de la cinasa de Jano JAK para el tratamiento de enfermedades, trastornos o afecciones. También se describen composiciones farmacéuticas que contienen tales compuestos.
MX2021013602A 2019-05-08 2020-05-07 Inhibidores de jak. MX2021013602A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845119P 2019-05-08 2019-05-08
US201962884588P 2019-08-08 2019-08-08
PCT/US2020/031925 WO2020227563A1 (en) 2019-05-08 2020-05-07 Jak inhibitors

Publications (1)

Publication Number Publication Date
MX2021013602A true MX2021013602A (es) 2022-04-06

Family

ID=73051620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013602A MX2021013602A (es) 2019-05-08 2020-05-07 Inhibidores de jak.

Country Status (13)

Country Link
US (1) US11136329B2 (es)
EP (1) EP3966209A4 (es)
JP (1) JP7617030B2 (es)
KR (1) KR20220052859A (es)
CN (1) CN114269734A (es)
AU (1) AU2020267661A1 (es)
BR (1) BR112021022380A2 (es)
CA (1) CA3139277A1 (es)
IL (1) IL287876A (es)
MX (1) MX2021013602A (es)
SG (1) SG11202112362YA (es)
TW (1) TWI865525B (es)
WO (1) WO2020227563A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020267661A1 (en) 2019-05-08 2021-12-23 Vimalan Biosciences, Inc. JAK inhibitors
BR112022002390A2 (pt) 2019-08-08 2022-06-14 Vimalan Biosciences Inc Inibidores de jak
CN114644633A (zh) * 2020-12-18 2022-06-21 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
KR102637915B1 (ko) * 2021-06-25 2024-02-19 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623032A1 (en) 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
AU2008211172A1 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases
WO2009098236A1 (en) 2008-02-06 2009-08-13 Novartis Ag Pyrrolo [2, 3-d] pyridines and use thereof as tyrosine kinase inhibitors
KR20120102601A (ko) 2009-10-20 2012-09-18 셀좀 리미티드 Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체
EA201291038A1 (ru) * 2010-04-30 2013-05-30 Целльзом Лимитид Соединения пиразола в качестве ингибиторов jak
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CA2849340A1 (en) * 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
ES2637245T3 (es) 2012-06-29 2017-10-11 Pfizer Inc. Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2
HK1250159A1 (zh) 2015-06-22 2018-11-30 小野药品工业株式会社 Brk抑制性化合物
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
AU2020267661A1 (en) 2019-05-08 2021-12-23 Vimalan Biosciences, Inc. JAK inhibitors
BR112022002390A2 (pt) 2019-08-08 2022-06-14 Vimalan Biosciences Inc Inibidores de jak
US20230024521A1 (en) 2019-09-25 2023-01-26 Vimalan Biosciences, Inc. Jak inhibitors

Also Published As

Publication number Publication date
BR112021022380A2 (pt) 2022-03-22
KR20220052859A (ko) 2022-04-28
JP2022532877A (ja) 2022-07-20
TWI865525B (zh) 2024-12-11
WO2020227563A1 (en) 2020-11-12
EP3966209A1 (en) 2022-03-16
JP7617030B2 (ja) 2025-01-17
CN114269734A (zh) 2022-04-01
IL287876A (en) 2022-01-01
US11136329B2 (en) 2021-10-05
EP3966209A4 (en) 2023-01-04
TW202108587A (zh) 2021-03-01
CA3139277A1 (en) 2020-11-12
AU2020267661A1 (en) 2021-12-23
US20200369669A1 (en) 2020-11-26
SG11202112362YA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
JOP20220087A1 (ar) أمينات ثنائية الحلقة كمثبطات لـ cdk2
EA202091709A1 (ru) Ингибиторы днк-пк
MX2021013602A (es) Inhibidores de jak.
EA202091708A1 (ru) Ингибиторы днк-пк
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MY205416A (en) Tyk2 inhibitors and uses thereof
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
MX383213B (es) Inhibidores de tirosina-cinasas
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
EA201990400A1 (ru) Соединения и композиции и их применение
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
EP4520395A3 (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
MX2022000712A (es) Moduladores de nlrp3.
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12022552447A1 (en) Nlrp3 modulators
BR112022005608A2 (pt) Inibidores de jak